16650-63-8

Usage

Uses

Used in Organic Synthesis:
3-BROMO-NAPHTHALENE-1-CARBOXYLIC ACID METHYL ESTER is used as a building block for the synthesis of new compounds, contributing to the development of novel chemical entities with potential applications in various fields.
Used in Pharmaceutical Research:
In the pharmaceutical industry, 3-BROMO-NAPHTHALENE-1-CARBOXYLIC ACID METHYL ESTER is used as a reagent in chemical reactions, aiding in the development of new drugs and pharmaceutical products. Its potential biological activity makes it a valuable component in drug discovery processes.
Used in Dye and Pigment Manufacturing:
3-BROMO-NAPHTHALENE-1-CARBOXYLIC ACID METHYL ESTER is utilized in the manufacturing of dyes and pigments, where its chemical properties contribute to the creation of a wide range of colorants for various applications.
Used in Industrial Chemical Production:
3-BROMO-NAPHTHALENE-1-CARBOXYLIC ACID METHYL ESTER also finds use in the production of other industrial chemicals, highlighting its versatility and importance in the chemical industry.

Upstream product

• 186581-53-3 diazomethane 
• 16726-66-2 3-bromo-1-naphthoic acid 
• 88790-90-3 methyl 3-amino-5,6,7,8-tetrahydro-1-naphthoate 
• 54978-07-3 3-nitro-1-naphthalenecarboxylic acid chloride 
• 4507-84-0 3-nitro-1-naphthoic acid 
• 67-56-1 methanol 
• 81-84-5 1,8-Naphthalic anhydride 
• 24050-49-5 3-bromonaphthalic-1,8-anhydride 

Downstream Products

• 79996-92-2 (3-bromonaphthalen-1-yl)methanol 
• 1354965-48-2 methyl 3-(4-phenyl-1H-1,2,3-triazol-1-yl)-1-naphthoate 
• 1354965-50-6 3-(4-phenyl-1H-1,2,3-triazol-1-yl)-1-naphthoic acid 
• 954410-14-1 C₃₈H₃₈FN₅O₅ 
• 954410-12-9 methyl 3-((3S)-3-(azidomethyl)-4-{[1-(3-ethoxyphenyl)-2-(2-fluoro-4-methylphenyl)-1H-imidazol-4-yl]carbonyl}piperazin-1-yl)-1-naphthoate 
• 954410-06-1 [(2S)-1-{[1-(3-ethoxyphenyl)-2-(2-fluoro-4-methylphenyl)-1H-imidazol-4-yl]carbonyl}-4-(4-{[(triisopropylsilyl)oxy]methyl}-2-naphthyl)piperazin-2-yl]methyl acetate 
• 1244017-19-3 methyl 3-(phenylethynyl)-1-naphthoate 
• 1033204-01-1 3-phenyl-naphthalene-1-carboxylic acid methyl ester 
• 1033204-02-2 3-(4-methoxy-phenyl)-naphthalene-1-carboxylic acid methyl ester 
• 1033204-03-3 3-(4-cyano-phenyl)-naphthalene-1-carboxylic acid methyl ester 

Relevant academic research and scientific papers

COMPOUNDS FOR THE INHIBITION OF CELLULAR PROLIFERATION

Compositions and methods for inhibiting translation are provided. Compositions, methods and kits for treating (1) cellular proliferative disorders, (2) non-proliferative, degenerative disorders, (3) viral infections, (4) disorders associated with viral infections, and/or (5) non-proliferative metabolic disorders such as type II diabetes where inhibition of translation initiation is beneficial using the compounds disclosed herein.

RENIN INHIBITORS

Renin inhibitors, which are spirocyclic piperidine amides, of structural formula (I) and pharmaceutical compositions thereof useful in the treatment of cardiovascular diseases and renal insufficiency, wherein n, for each instance in which it occurs, is independently 0, 1, or 2; R1 is hydrogen, C1-6 -alkyl or C3-6 -cycloalkyl, wherein said C1-6 -alkyl or C3-6 -cycloalkyl group can be independently substituted with 1-3 halogens; A is (i) a five- or six-membered saturated or unsaturated heterocyclic or carbocyclic monocyclic ring or (ii) a five- or six-membered saturated or unsaturated heterocyclic or carbocyclic ring which is fused to another five- or six-membered saturated or unsaturated heterocyclic or carbocyclic ring, V is a bond or -(C=O)-, -CH(OH)-, -CH2- or =CH-; U is a bond or -CH2-, or for the case when V is =CH-, U is -CH=; X is =CH-, =CF-, =C(OR3)-, or -C=O-; and Y is =CH-, =CF-, =N-, or for the case when X is -C=O-, Y is -N(R3)-.

Substituted Imidazole 4-Carboxamides as Cholecystokinin-1 Receptor Modulators

Certain novel substituted imidazole 4-carboxamides are ligands of the human cholecystokinin receptor and, in particular, are selective ligands of the human cholecystokinin-1 receptor (CCK-1R). They are therefore useful for the treatment, control, or prevention of diseases and disorders responsive to the modulation of CCK-1R, such as obesity, and diabetes.

A rapid, large-scale synthesis of a potent cholecystokinin (CCK) 1R receptor agonist

The development of a scalable synthesis of a potent cholecystokinin (CCK) IR receptor agonist is described. The focus on a rapid short-term delivery rather than longer-term development allowed for the preparation of multihundred gram quantities to support

SUBSTITUTED IMIDAZOLE 4-CARBOXAMIDES AS CHOLECYSTOKININ-1 RECEPTOR MODULATORS

Certain novel substituted imidazole 4-carboxamides are ligands of the human cholecystokinin receptor and, in particular, are selective ligands of the human cholecystokinin-1 receptor (CCK-1R). They are therefore useful for the treatment, control, or prevention of diseases and disorders responsive to the modulation of CCK-1R, such as obesity, and diabetes.

The mercury-mediated decarboxylation (Pesci reaction) of naphthoic anhydrides investigated by microwave synthesis

The mercury-mediated decarboxylation (Pesci reaction) of several substituted naphthoic anhydrides has been investigated by microwave synthesis. A laboratory microwave reactor was found to be ideal for small-scale preparations of this slow reaction, reducing reaction times from typically four days to less than 1 h for the three-step process. The ionic reaction medium rapidly heated to high temperatures under microwave heating and could be efficiently maintained by low microwave power settings. Generation of stoichiometric CO2 was safely contained within the reaction tubes. A simplified reaction procedure has been developed. For substituted naphthoic anhydrides, 1H NMR analysis of the naphthoate ester derivatives indicated no change in the regioisomer ratio compared to previously reported thermal values.

A new approach to rapid parallel development of four neurokinin antagonists. Part 2. Synthesis of ZD6021 cyano acid

The manufacture of ZD6021 cyano acid (1) using a new project approach is described. Research Department processes were scaled up to 100 L if process safety anal robustness were not compromised; other factors were treated according to the new approach. By using this strategy, we were able to manufacture a key intermediate on sufficient scale to support delivery of 1 kg quantities of bulk drug within 6 months of the start of lab work.

Discovery of novel, orally active dual NK1/NK2 antagonists

Exploration of the SAR around selective NK2 antagonists, SR48968 and ZD7944, led to the discovery that naphth-1-amide analogues provide potent dual NK1 and NK2 antagonists. ZD6021 inhibited binding of [3H]-NKA or [3H]-SP to human NK1 and NK2 receptors, with high-affinity (Ki=0.12 and 0.62 nM, respectively). In functional assays ZD6021 had, at 10-7 M, in human pulmonary artery pKB=8.9 and in human bronchus pKB=7.3, for NK1 and NK2, respectively. Oral administration of ZD6021 to guinea pigs dose-dependently attenuated ASMSP induced extravasation of plasma proteins, ED50=0.5 mg/kg, and NK2 mediated bronchoconstriction, ED50=13 mg/kg.

Preparation of a series of substituted fluoromethylnaphthalenes

A series of 22 3- and 4-substituted 1-fluoromethylnaphthalenes have been synthesized.Details of practical procedures for the preparation of all intermediates are described, and physical properties for all of the substituted naphthalenes synthesized, and spectral parameters for 51 previously unknown compounds, are given.